DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1728 reductase activity contributes to fludarabine resistance.
Biochem Pharmacol, 2003, 65:237–247.
Matijasevic Z, Boosalis M, Mackay W, et al. Protection
against chloroethylnitrosourea cytotoxicity by eukaryotic
3-methyladenine DNA glycosylase. Proc Natl Acad Sci U S A,
1993, 90:11855–11859.
Meijer C, Mulder NH, Hospers GA, et al. The role of glutathione
in resistance to cisplatin in a human small cell lung cancer cell
line. Br J Cancer, 1990, 62:72–77.
Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine
dehydrogenase deficiency and fluorouracil-related toxicity. Br
J Cancer, 1999, 79:627–630.
Miyake K, Mickley L, Litman T, et al. Molecular cloning of
cDNAs which are highly overexpressed in mitoxantroneresistant
cells: Demonstration of homology to ABC transport
genes. Cancer Res, 1999, 59:8–13.
Moeller A, Ask K, Warburton D, et al. The bleomycin animal
model: A useful tool to investigate treatment options for idiopathic
pulmonary fibrosis? Int J Biochem Cell Biol, 2008,
40:362–382.
Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-
Farber Cancer Institute ALL Consortium Protocol 95-01 for
children with acute lymphoblastic leukemia. Blood, 2007,
109:896–904.
Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor of
the potential treatment of several malignancies. IDrugs, 2008,
11:508–521.
Myers CE. Role of iron in anthracycline action. In: Hacker MP,
Lazo JS, Tritton TR, eds. Organ-Directed Toxicities of
Anticancer Drugs. Boston, Nijhoff, 1988, pp. 17–30.
Neubauer A, Maharry K, Mrózek K, et al. Patients with acute
myeloid leukemia and RAS mutations benefit most from
postremission high-dose cytarabine: A Cancer and Leukemia
Group B study. J Clin Oncol, 2008, 26:4603–4609.
Nicolao P, Giometto B. Neurological toxicity of ifosfamide.
Oncology, 2003, 65:11–16.
Nicolaou KC, Yang Z, Liu JJ, et al. Total synthesis of Taxol.
Nature, 1994, 367:630–634.
Nilsson C, Aschan J, Ringden O, et al. The effect of metronidazole
on busulfan pharmacokinetics in patients undergoing
hemapoietic stem cell transplantation. Bone Marrow
Transplant, 2003, 31:429–435.
O’Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a
novel class of antifol with high affinity for the reduced folate
carrier-type 1, produces marked complete and durable remission
in a diversity of chemotherapy refractory cases of T-cell
lymphoma. Br J Haematol, 2007, 139:425–428.
Ohhashi S, Ohuchida K, Mizumoto K, et al. Down-regulation of
deoxycytidine kinase enhances acquired resistance to gemcitabine
in pancreatic cancer. Anticancer Res, 2008, 28:
2205–2212.
Oki Y, Aoki E, Issa JP. Decitabine—Bedside to bench. Crit Rev
Oncol Hematol, 2007, 61:140–152.
O’Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and
pharmacologic study of topotecan in patients with impaired
renal function. J Clin Oncol, 1996, 14:3062–3073.
O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the
risk of bleomycin lung toxicity in patients with germ-cell
tumours. Ann Oncol, 2003, 14:91–96.
Paré L, Marcuello E, Altés A, et al. Pharmacogenetic prediction
of clinical outcome in advanced colorectal cancer patients
SECTION VIII
CHEMOTHERAPY OF NEOPLASTIC DISEASES
receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
Br J Cancer, 2008, 99:1050–1055. Erratum in: Br J Cancer,
2009, 100:1368.
Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional
trial of the histone deacetylase inhibitor romidepsin as
monotherapy for patients with cutaneous T-cell lymphoma. J
Clin Oncol, 2009, 27:5410–5417.
Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients
treated with depsipeptide, FK228, in a phase II trial for T-cell
lymphoma. Clin Cancer Res, 2006, 12:3762–3773.
Platt OS. Hydroxyurea for the treatment of sickle cell anemia.
N Engl J Med, 2008, 358:1362–1369.
Plunkett W, Gandhi V. Cellular metabolism of nucleoside
analogs in CLL: Implications for drug development. In:
Cheson B, ed. Chronic Lymphocytic Leukemia: Scientific
Advances and Clinical Developments. New York, Marcel
Dekker, 1993, p. 197.
Pui CH, Relling MV, Downing JR. Mechanisms of disease:
Acute lymphoblastic leukemia. N Engl J Med, 2004, 350:
1535–1548.
Pui CH, Relling MV, Rivera GK, et al. Epipodophyllotoxinrelated
acute myeloid leukemia: A study of 35 cases.
Leukemia, 1995, 9:1990–1996.
Preisler HD, Rustum Y, Priore RL. Relationship between leukemic
cell retention of cytosine arabinoside triphosphate and the duration
of remission in patients with acute non-lymphocytic
leukemia. Eur J Cancer Clin Oncol, 1985, 21:23–30.
Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase
gene polymorphism determines response and toxicity of
5-FU chemotherapy. Pharmacogenomics J, 2001, 1:65–70.
Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered betatubulin
isotype expression in paclitaxel-resistant human
prostate carcinoma cells. Br J Cancer, 1998, 77:562–566.
Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis
associated with docetaxel administration. Cancer, 2002,
94:847–853.
Reed E. Platinum-DNA adduct, nucleotide excision repair and
platinum based anti-cancer chemotherapy. Cancer Treat Rev,
1998, 24:331–344.
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of
bortezomib in relapsed, refractory myeloma. N Engl J Med,
2003, 348:2609–2617.
Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of
vinorelbine in patients with liver metastases. Clin Pharmacol
Ther, 1996, 59:32–40.
Roussel MJ, Lanotte M. Maturation sensitive and resistant
t(15,17) NB4 cell lines as tools for APL physiopathology,
nomenclature of cells and repertory of their known genetic
alterations and phenotypes. Oncogene, 2001, 20:7287–7291.
Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med, 1995,
332:1004–1014.
Sanford M, Lyseng-Williamson KA. Nelarabine. Drugs, 2008,
68:439–447.
Schimke RT, Kaufman RJ, Alt FW, Kellems RF. Gene amplification
and drug resistance in cultured murine cells. Science,
1978, 202:1051–1055.
Sebti SM, Jani JP, Mistry JS, et al. Metabolic inactivation: A
mechanism of human tumor resistance to bleomycin. Cancer
Res, 1991, 51:227–232.
Serrano J, Palmeira CM, Kuehl DW, Wallace KB.
Cardioselective and cumulative oxidation of mitochondrial